BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32337716)

  • 21. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
    Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
    N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Kinoshita A; Miyachi H; Matsushita H; Yabe M; Taki T; Watanabe T; Saito AM; Tomizawa D; Taga T; Takahashi H; Matsuo H; Kodama K; Ohki K; Hayashi Y; Tawa A; Horibe K; Adachi S
    Br J Haematol; 2014 Oct; 167(1):80-6. PubMed ID: 25039450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapy.
    Reisbach G; Kamp T; Welzl G; Geiz C; Abedinpour Fariborz ; Lodri A; Kaboth W; Dörmer P; Nerl C
    Br J Haematol; 1996 Mar; 92(4):907-12. PubMed ID: 8616084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?
    Bennett CL; Schumock GT
    Drugs Aging; 2003; 20(7):479-83. PubMed ID: 12749746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of acute myelogenous leukaemia.
    Löwenberg B
    J Intern Med Suppl; 1997; 740():17-22. PubMed ID: 9350177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
    Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].
    Mori H; Kuriyama K; Tawara M; Danno Y; Fujimoto K; Tushima H; Saito M; Yamamura M; Hata T; Arimura M
    Rinsho Ketsueki; 1995 Jul; 36(7):648-56. PubMed ID: 7563592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study.
    Usuki K; Urabe A; Masaoka T; Ohno R; Mizoguchi H; Hamajima N; Miyazaki T; Niitsu Y; Yoshida Y; Miura A; Shibata A; Abe T; Miura Y; Ikeda Y; Nomura T; Nagao T; Saitou H; Shirakawa S; Ohkuma M; Matsuda T; Nakamura T; Horiuchi A; Kuramoto A; Kimura I; Irino S; Niho Y; Takatsuki K; Tomonaga M; Uchino H; Takaku F;
    Br J Haematol; 2002 Jan; 116(1):103-12. PubMed ID: 11841402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
    Braess J; Spiekermann K; Staib P; Grüneisen A; Wörmann B; Ludwig WD; Serve H; Reichle A; Peceny R; Oruzio D; Schmid C; Schiel X; Hentrich M; Sauerland C; Unterhalt M; Fiegl M; Kern W; Buske C; Bohlander S; Heinecke A; Baurmann H; Beelen DW; Berdel WE; Büchner T; Hiddemann W
    Blood; 2009 Apr; 113(17):3903-10. PubMed ID: 19131552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
    Freedman MH; Bonilla MA; Fier C; Bolyard AA; Scarlata D; Boxer LA; Brown S; Cham B; Kannourakis G; Kinsey SE; Mori PG; Cottle T; Welte K; Dale DC
    Blood; 2000 Jul; 96(2):429-36. PubMed ID: 10887102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
    Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length.
    Li AM; Thyagu S; Maze D; Schreiber R; Sirrs S; Stockler-Ipsiroglu S; Sutherland H; Vercauteren S; Schultz KR
    Pediatr Hematol Oncol; 2018 Feb; 35(1):45-51. PubMed ID: 29652549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.